Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic pulses to the brain may tame Parkinson's drug side effects

NCT ID NCT06570824

Disease control Sponsor: Danish Research Centre for Magnetic Resonance Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether repetitive transcranial magnetic stimulation (rTMS) can reduce or delay the involuntary movements, called dyskinesia, that many Parkinson's patients develop after taking levodopa. Researchers will apply targeted magnetic pulses to a brain region involved in movement planning, the pre-supplementary motor area, in about 68 people with Parkinson's who experience these peak-dose movements. Half will receive real stimulation and half a sham version, allowing a fair comparison of effects on dyskinesia severity and onset time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Repetitive transcranial magnetic stimulation (rTMS) using a MagVenture device, targeting the pre-supplementary motor area of the brain
What this could lead to
If it works, this could offer a non-drug way to ease the involuntary movements that many Parkinson's patients experience when their levodopa medication kicks in.
What could go wrong
This is an early-stage trial with a modest number of participants, and the effect may be small or short-lived. Brain stimulation can also cause discomfort or, rarely, seizures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 68 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinically established or probable PD * Clinical Diagnostic Criteria for Parkinson's Disease * Peak-of-dose levodopa-induced dyskinesia. * Stable antiparkinsonian medicine for at least four weeks. * Signed informed consent. Exclusion Criteria: * Psychiatric disorders. * Usage of antipsychotic medication, Donepezil, and GABAergic medications (such as pregabalin and gabapentin). * Regular usage of benzodiazepines and opioids (more than once per week). * History of neurological disease other than Parkinson's disease. * History of epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Close relatives suffering from epilepsy/conditions associated with increased risk to seizure-induction through TMS. * Contraindications for MRI scan * Female participants of childbearing age must not be pregnant and that they must use contraception during the trial. * Refuse to be informed about new health related information and accidental health related findings that might appear through participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyskinesia, drug-induced are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal ganglia disorder central nervous system disorder drug-induced dyskinesia Dyskinesias movement disorder neurodegenerative disease Parkinson disease synucleinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyskinesia, drug-induced Parkinson disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • DRCMR

    RECRUITING

    Hvidovre, 2650, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.